- Home
- WSC vs OGN Comparison
WSC vs OGN Comparison
Compare WSC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WSC | OGN |
|---|---|---|
| Founded | 1944 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WSC | OGN |
|---|---|---|
| Price | $20.03 | $7.17 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $25.43 | $14.10 |
| AVG Volume (30 Days) | 4.0M | ★ 4.9M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.37% | 1.12% |
| EPS Growth | ★ 816.06 | N/A |
| EPS | 1.20 | ★ 1.91 |
| Revenue | $2,317,990,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.00 | ★ $3.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.91 | $6.18 |
| 52 Week High | $39.61 | $17.23 |
Technical Indicators
Market Signals| Indicator | WSC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 44.45 |
| Support Level | $20.08 | $7.05 |
| Resistance Level | $21.45 | $7.49 |
| Average True Range (ATR) | 0.96 | 0.29 |
| MACD | 0.20 | 0.03 |
| Stochastic Oscillator | 55.38 | 28.80 |
Price Performance
Historical ComparisonAbout WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.